Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Lord Strasburger, and are more likely to reflect personal policy preferences.
Lord Strasburger has not introduced any legislation before Parliament
Lord Strasburger has not co-sponsored any Bills in the current parliamentary sitting
The National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) have dedicated funding to research into treatment options, clinical trials, and to understanding the underlying mechanisms of long COVID. The overall Government investment in long COVID research is over £57 million. Government research funders welcome applications for funding for long COVID research.
Of the research studies identified in the answer for HL5426, four are ongoing and have expected spend in this financial year, namely: STIMULATE-ICP; PHOSP-COVID; Percutaneous Auricular Nerve Stimulation for Treating Post-COVID Fatigue; and Online cognitive training for people with cognitive impairment following SARS-CoV-2 infection. The total budget for these studies is over £15 million, but spend in this financial year is not yet confirmed, as it depends on the progress of the studies.
No specific assessment has been made of the progress of United Kingdom-based researchers on finding methods to treat the symptoms of long COVID. The UK has a strong track record of developing and evaluating new treatments for COVID-19 through randomised control trials. In November 2020, the NIHR and UKRI launched their first call for research proposals on long COVID and subsequently funded the treatments for long COVID. In 2021, the NIHR funded the STIMULATE-ICP study as the largest trial for long COVID treatments at the time. This study is still ongoing, and emerging findings will be shared with the National Institute for Health and Care Excellence. The NIHR Innovation Observatory has undertaken a rapid horizon scan to identify repurposed medicines in clinical development for the treatment of myalgic encephalomyelitis, also known as chronic fatigue syndrome, as well as related conditions such as long COVID and fibromyalgia. The horizon scan focused on medicines with a UK licence that are in phase two or three clinical trials, with trial registration dates from 2020 onwards.
Unfortunately, no study globally has identified a cure for long COVID. The REGAIN study became the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high quality evidence confirming the sustained clinical benefit and lack of harm from rehabilitation programmes for long COVID. The NIHR provided £1.5 million towards this trial, which combined exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.
The National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) have dedicated funding to research into treatment options, clinical trials, and to understanding the underlying mechanisms of long COVID. The overall Government investment in long COVID research is over £57 million. Government research funders welcome applications for funding for long COVID research.
Of the research studies identified in the answer for HL5426, four are ongoing and have expected spend in this financial year, namely: STIMULATE-ICP; PHOSP-COVID; Percutaneous Auricular Nerve Stimulation for Treating Post-COVID Fatigue; and Online cognitive training for people with cognitive impairment following SARS-CoV-2 infection. The total budget for these studies is over £15 million, but spend in this financial year is not yet confirmed, as it depends on the progress of the studies.
No specific assessment has been made of the progress of United Kingdom-based researchers on finding methods to treat the symptoms of long COVID. The UK has a strong track record of developing and evaluating new treatments for COVID-19 through randomised control trials. In November 2020, the NIHR and UKRI launched their first call for research proposals on long COVID and subsequently funded the treatments for long COVID. In 2021, the NIHR funded the STIMULATE-ICP study as the largest trial for long COVID treatments at the time. This study is still ongoing, and emerging findings will be shared with the National Institute for Health and Care Excellence. The NIHR Innovation Observatory has undertaken a rapid horizon scan to identify repurposed medicines in clinical development for the treatment of myalgic encephalomyelitis, also known as chronic fatigue syndrome, as well as related conditions such as long COVID and fibromyalgia. The horizon scan focused on medicines with a UK licence that are in phase two or three clinical trials, with trial registration dates from 2020 onwards.
Unfortunately, no study globally has identified a cure for long COVID. The REGAIN study became the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high quality evidence confirming the sustained clinical benefit and lack of harm from rehabilitation programmes for long COVID. The NIHR provided £1.5 million towards this trial, which combined exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.
The National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) have dedicated funding to research into treatment options, clinical trials, and to understanding the underlying mechanisms of long COVID. This investment spans both infrastructure supported projects and programme awards.
The total funding for the research studies, which include at least one element on treatments, is over £16.2 million. We have provided the overall figures of investment into the relevant studies, although not all funding would have been directly spent on treatments or clinical trials, which are as follows:
The most recent data from the Winter Coronavirus (COVID-19) Infection Study, a joint study carried out by the Office for National Statistics (ONS) and the UK Health Security Agency, shows that, for the period 6 February 2024 to 7 March 2024, an estimated 1.8 million people, or 3.3% of the population, in private households in England, self-reported experiencing long COVID symptoms more than four weeks after a COVID-19 infection. The following table shows a breakdown of duration:
Duration | Estimate |
4 to 11 weeks | 148,971 |
12 to 25 weeks | 105,946 |
26 to 38 weeks | 28,107 |
39 to 51 weeks | 57,164 |
52 to 77 weeks | 105,962 |
78 to 103 weeks | 116,876 |
104 to 155 weeks | 253,770 |
156 weeks and over | 365,922 |
No estimate has been made of the rate at which prevalence of long COVID is currently increasing or decreasing in England. The ONS does not regularly collect this data.
No estimate has been made of the effect of long COVID on the economy in each year from 2020 to 2024, including the effect with respect to those affected by long COVID of their economic inactivity, the diminution in their quality of life, their lost income, the cost of informal caregiving for them, and their extra healthcare costs.
The most recent data from the infection study shows that for those who self-report long COVID of any duration, in England and Scotland, who are aged between 16 and 64 years old and are not in education are less likely to be employed or self-employed compared with those who have not reported long COVID.
On 18 December 2020, NHS England had put in place 69 dedicated clinics across the country. As of 1 April 2024, there were over 90 adult post-COVID services across England along with an additional 10 children and young people’s hubs.
The most recent data from the Winter Coronavirus (COVID-19) Infection Study, a joint study carried out by the Office for National Statistics (ONS) and the UK Health Security Agency, shows that, for the period 6 February 2024 to 7 March 2024, an estimated 1.8 million people, or 3.3% of the population, in private households in England, self-reported experiencing long COVID symptoms more than four weeks after a COVID-19 infection. The following table shows a breakdown of duration:
Duration | Estimate |
4 to 11 weeks | 148,971 |
12 to 25 weeks | 105,946 |
26 to 38 weeks | 28,107 |
39 to 51 weeks | 57,164 |
52 to 77 weeks | 105,962 |
78 to 103 weeks | 116,876 |
104 to 155 weeks | 253,770 |
156 weeks and over | 365,922 |
No estimate has been made of the rate at which prevalence of long COVID is currently increasing or decreasing in England. The ONS does not regularly collect this data.
No estimate has been made of the effect of long COVID on the economy in each year from 2020 to 2024, including the effect with respect to those affected by long COVID of their economic inactivity, the diminution in their quality of life, their lost income, the cost of informal caregiving for them, and their extra healthcare costs.
The most recent data from the infection study shows that for those who self-report long COVID of any duration, in England and Scotland, who are aged between 16 and 64 years old and are not in education are less likely to be employed or self-employed compared with those who have not reported long COVID.
On 18 December 2020, NHS England had put in place 69 dedicated clinics across the country. As of 1 April 2024, there were over 90 adult post-COVID services across England along with an additional 10 children and young people’s hubs.
The Government recognises that long COVID is a complex condition, with a wide range of symptoms, which, in the worst case, can be substantially incapacitating. The term ‘long COVID’ is an umbrella term, coined by patients and widely used to describe a wide range of symptoms or clusters of symptoms, of differing duration and severity, and potentially a number of distinct syndromes. The clinical case definition produced by the National Institute for Health and Care Excellence identifies three phases of post-COVID-19 infection, the latter two of which are commonly described as long COVID, which are as follows:
The most common symptoms of long COVID are extreme tiredness or fatigue, feeling short of breath, problems with your memory and concentration, sometimes referred to as brain fog, heart palpitations, dizziness, joint pain, and muscle aches.
Details of the pilot schemes carried out by South Wales Police will be set out in due course as part of a wider publication by the Home Office on its approach to the use of live facial recognition technology.